BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has received approval from Health Canada to start its 'Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease,' it was reported on Wednesday.
This is the first trial in Canada to assess pluripotent stem cell-derived dopaminergic neurons in subjects with Parkinson's disease. The company is enrolling 10 patients in the United States and Canada for the trial, with the Canadian trial site at University Health Network, a research and teaching hospital network located in Toronto, Ontario.
The Ph1 study's primary objective is to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval